1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services; 2012 Mar 27.
2. von Hentig N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc). 2008;44(2):103–32.
3. Bristol Myers Squibb Company. Princeton, NJ, USA. Reyataz product information. 2012.
4. Giguere P, Burry J, Beique L, Zhang G, Angel J, la Porte C. The effect of food on the pharmacokinetics of atazanavir/ritonavir 300/100 mg daily in HIV-infected patients. 11th International Workshop on Clinical Pharmacology and HIV Therapy. 2010 Apr 7. Report No. 30: Sorrento, Italy.
5. Bruyere A, Decleves X, Bouzom F, Ball K, Marques C, Treton X, et al. Effect of Variations in the Amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the Human Small Intestine on PBPK Models for Predicting Intestinal First Pass. Mol Pharm. 2010;7(5):1596–607.